A Phase 3 clinical trial studying ecnoglutide injection was registered on September 23, 2026. The trial is titled "A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents." Its current status is listed as not yet recruiting. The study is registered under the identifier NCT07836270. Ecnoglutide remains an unapproved compound currently in research use only. No participants have been enrolled at this stage, and no outcomes or results have been reported for this trial. The registration reflects the planned scope of the study, which targets an adolescent population described as overweight or obese, in China. Further updates would typically follow as the trial moves toward active recruitment. Readers interested in ecnoglutide's regulatory background and research history can consult the compound overview for additional context.
Phase 3 Trial of Ecnoglutide in Obese Adolescents Registered
See the full ecnoglutide overview
Source: https://clinicaltrials.gov/study/NCT07836270